CellSource Co., Ltd. (4880) AI Stock Analysis

• Market Cap: ¥10.13B
• Dividend Yield: 1.01%
• Average Volume (3M): 77.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: -13.81%
• EPS Growth: -107.95%
• Country: JP
• Employees: 151
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.79
• Shares Outstanding: 19,819,962
• 10 Day Avg. Volume: 73,510
• 30 Day Avg. Volume: 77,646
• PEG Ratio: -1.31
• Price to Book (P/B): 3.89
• Price to Sales (P/S): 5.40
• P/FCF Ratio: 451.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ¥547.00 ▲(9.40% Upside)

The overall stock score is primarily influenced by the company's strong financial performance, which provides a stable foundation despite recent challenges. However, technical analysis indicates bearish momentum, and the valuation is concerning due to a negative P/E ratio. These factors result in a moderate overall score.

CellSource Co., Ltd. Business Overview & Revenue Model

Company Description

CellSource Co., Ltd. (4880) is a biotechnology company focused on the development and commercialization of innovative cellular therapies. The company operates primarily in the healthcare sector, specializing in stem cell research and regenerative medicine. CellSource's core products include advanced cellular treatments for various diseases and conditions, leveraging proprietary technology to enhance the efficacy and safety of therapies. The firm aims to transform patient care through its cutting-edge solutions that address unmet medical needs.

How the Company Makes Money

CellSource Co., Ltd. generates revenue primarily through the sale of its cellular therapy products and services, which are marketed to hospitals, clinics, and research institutions. The company's revenue model includes direct sales of its therapies as well as partnerships with pharmaceutical firms for co-development and licensing agreements. Additionally, CellSource may earn income through grants and funding for research and development projects in collaboration with academic institutions and government bodies. Significant partnerships with key players in the biotechnology and pharmaceutical industries further bolster its revenue streams, enabling shared resources and expanded market access.

CellSource Co., Ltd. Financial Statement Overview

Summary

CellSource Co., Ltd. exhibits a strong financial foundation with stable revenue growth, effective cost management, and a robust equity position. Recent declines in net income and revenue growth present challenges, but the company's low leverage and solid cash flow generation provide a cushion for future stability and growth.

Income Statement

CellSource Co., Ltd. has shown a consistent increase in total revenue over the years, demonstrating strong growth in the biotechnology sector. However, the latest year saw a slight decline in revenue. The gross profit margin is solid, indicating efficient cost management. The company has maintained a healthy net profit margin, although it has decreased recently due to lower net income. Overall, the income statement reflects a stable revenue base with some recent challenges in profitability.

Balance Sheet

The company's balance sheet reveals a robust financial position with a strong equity base and minimal debt, reflected in a low debt-to-equity ratio. The equity ratio is high, indicating a well-capitalized structure. Return on equity has decreased, correlating with the drop in net income, but remains positive. Overall, the balance sheet reflects financial stability and low leverage risk.

Cash Flow

CellSource has generated consistent operating cash flow, supporting its operations. Free cash flow has been positive, though its growth has been moderate recently. The operating cash flow to net income ratio is healthy, suggesting effective cash management. However, the recent decline in free cash flow growth highlights potential challenges in sustaining cash flow growth. Overall, the cash flow statement indicates solid cash generation with room for improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.93B	4.36B	4.51B	4.27B	2.92B	1.86B
Gross Profit	1.72B	2.42B	3.18B	3.06B	2.07B	1.26B
EBITDA	266.40M	449.53M	1.31B	1.64B	1.06B	476.46M
Net Income	85.40M	237.94M	923.14M	1.02B	651.40M	274.08M
Balance Sheet
Total Assets	6.94B	7.07B	6.88B	4.60B	3.37B	2.35B
Cash, Cash Equivalents and Short-Term Investments	4.41B	4.32B	4.78B	3.12B	2.41B	1.76B
Total Debt	46.31M	77.29M	97.54M	0.00	1.10M	7.29M
Total Liabilities	994.15M	1.04B	677.74M	814.15M	645.00M	309.63M
Stockholders Equity	5.95B	6.04B	6.20B	3.79B	2.72B	2.04B
Cash Flow
Free Cash Flow	0.00	52.04M	487.69M	748.44M	836.74M	297.50M
Operating Cash Flow	0.00	591.72M	846.69M	847.60M	898.19M	330.23M
Investing Cash Flow	0.00	-614.96M	-624.08M	-169.39M	-256.12M	-57.83M
Financing Cash Flow	0.00	-437.24M	1.45B	14.42M	9.35M	152.65M

CellSource Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 500.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Negative. The current price of 500 is below the 20-day moving average (MA) of 512.35, below the 50-day MA of 553.20, and below the 200-day MA of 672.05, indicating a bearish trend. The MACD of -18.17 indicates Negative momentum. The RSI at 37.02 is Neutral, neither overbought nor oversold. The STOCH value of 19.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4880.

CellSource Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	61 Neutral	¥8.30B	33.05	―	―	4.58%	-39.30%
4880	55 Neutral	¥10.13B	-202.30	―	1.01%	-13.81%	-107.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4978	49 Neutral	¥15.92B	―	―	―	13.83%	34.66%
4599	47 Neutral	¥16.96B	-8.77	―	―	―	5.58%
4888	46 Neutral	¥10.58B	-77.98	―	―	268.05%	83.57%
7776	46 Neutral	¥15.15B	-14.61	―	―	-22.81%	2.69%

CellSource Co., Ltd. Corporate Events

CellSource Stock Gains Loan Margin Trading Status

CellSource Co., Ltd. has announced that its stock has been newly selected as a Loan Margin Trading Issue on the Japan Securities Finance Co., Ltd., effective October 14, 2025. This selection is expected to enhance the liquidity and supply-demand balance of the company’s stock, promoting active trading and fair pricing.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports September 2025 KPI Results

CellSource Co., Ltd. reported its September 2025 KPI results for contract processing services, noting a stable daily average number of orders at 51.2. The company saw a significant shift in order distribution, with a decrease in self-funded orthopedics orders and an increase in hybrid orthopedics. Efforts are being made to address the decline in self-funded orders through strategic reviews and support services, while initiatives for hybrid orthopedics continue to target key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Reports Nine-Month Financial Results and Positive Full-Year Outlook

CellSource Co., Ltd. reported its consolidated financial results for the nine months ending July 31, 2025, showing net sales of ¥2,818 million and a profit attributable to owners of ¥86 million. The company has shifted to consolidated accounting, making year-on-year comparisons unavailable, but it forecasts full-year net sales of ¥3,774 million and a profit of ¥112 million, indicating a positive outlook for the fiscal year.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Revises Financial Forecasts Amid Contract Changes

CellSource Co., Ltd. has revised its financial forecast for the fiscal year ending October 31, 2025, due to lower-than-expected net sales and profit. The revision is attributed to changes in contract terms for medical institution support services and slower-than-anticipated results from measures to increase orders for contract processing services. The company expects flat sales in contract processing services for self-funded medical institutions and anticipates increased orders from hybrid-type institutions in the fourth quarter.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports Decline in July 2025 Contract Processing Orders

CellSource Co., Ltd. reported a decrease in its July 2025 contract processing orders, with a significant drop in blood-derived product orders for hybrid orthopedics. Despite the decline, the company remains committed to strengthening its organizational structure and maintaining planned order volumes, while continuing initiatives with key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.